Resumen
El desarrollo de nuevos fármacos bloqueadores del receptor P2Y12, como el prasugrel y el ticagrelor, con un efecto más rápido, más potente y con menor variabilidad que el del clopidogrel, ha llevado a plantear las preguntas de si sigue siendo necesaria la administración de inhibidores de la glucoproteína IIb/IIIa en los pacientes con un síndrome coronario agudo de alto riesgo y si es segura la combinación de ambos tipos de fármacos debido al riesgo de sangrado. El objetivo de este artículo es aportar una visión general del estado actual de conocimiento de la eficacia de los fármacos antiagregantes disponibles, prestando especial atención a la variabilidad interindividual de respuesta al clopidogrel, al efecto antiplaquetario de los inhibidores de la glucoproteína IIb/IIIa y de los nuevos antagonistas del receptor P2Y12, así como a las evidencias disponibles sobre la asociación de ambos grupos de fármacos.
Palabras clave
Clopidogrel
Prasugrel
Ticagrelor
Inhibidores de la glucoproteína IIb/IIIa
Abreviaturas
AAS
ADP
COX
CYP
GP
IAMCEST
ICP
IGP
SCA
SCASEST
Este artículo solo puede leerse en
pdf
Bibliografía
[1.]
G. Davì, C. Patrono.
Platelet activation and atherothrombosis.
N Engl J Med, (2007), 357 pp. 2482-2494
[2.]
D.J. Angiolillo, M. Ueno, S. Goto.
Basic principles of platelet biology and clinical implications.
Circ J, (2010), 74 pp. 597-607
[3.]
S. Kulkarni, S.M. Dopheide, C.L. Yap, C. Ravanat, M. Freund, P. Mangin, et al.
A revised model of platelet aggregation.
J Clin Invest, (2000), 105 pp. 783-791
[4.]
D.R. Phillips, L. Nannizzi-Alaimo, K.S. Prasad.
Beta3 tyrosine phosphorylation in alphaIIbbeta3 (platelet membrane GP IIb-IIIa) outside-in integrin signaling.
Thromb Haemost, (2001), 86 pp. 246-258
[5.]
J.P. Bassand, C.W. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernández-Avilés, et al.
Guía de Práctica Clínica para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST.
Rev Esp Cardiol, (2007), 60
[6.]
F. Van de Werf, J. Bax, A. Betriu, C. Blomstrom-Lundqvist, F. Crea, V. Falk, et al.
Guía de práctica clínica de la Sociedad Europea de Cardiología (ESC). Manejo del infarto agudo de miocardio en pacientes con elevación persistente del segmento ST.
Rev Esp Cardiol, (2009), 62
[7.]
W. Wijns, P. Kolh, N. Danchin, C. Di Mario, V. Falk, T. Folliguet, et al.
Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).
Eur Heart J, (2010),
[8.]
S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicius, G. Tognoni, K.K. Fox.
Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
N Engl J Med, (2001), 345 pp. 494-502
[9.]
S.R. Steinhubl, P.B. Berger, J.T. Mann, E.T. Fry, A. DeLago, C. Wilmer, CREDO Investigators, et al.
Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
JAMA, (2002), 288 pp. 2411-2420
[10.]
Z.M. Chen, L.X. Jiang, Y.P. Chen, J.X. Xie, H.C. Pan, R. Peto, COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group, et al.
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.
Lancet, (2005), 366 pp. 1607-1621
[11.]
M. Roffi, D.P. Chew, D. Mukherjee, D.L. Bhatt, J.A. White, D.J. Moliterno, et al.
Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy.
Eur Heart J, (2002), 23 pp. 1441-1448
[12.]
A. Kastrati, J. Mehilli, F.J. Neumann, F. Dotzer, J. Ten Berg, H. Bollwein, Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators, et al.
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
JAMA, (2006), 295 pp. 1531-1538
[13.]
G. De Luca, E. Navarese, P. Marino.
Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials.
Eur Heart J, (2009), 30 pp. 2705-2713
[14.]
J.L. Ferreiro, D.J. Angiolillo.
Clopidogrel response variability: current status and future directions.
Thromb Haemost, (2009), 102 pp. 7-14
[15.]
D.J. Angiolillo, J.L. Ferreiro.
Inhibición del receptor plaquetario P2Y 12 de adenosina difosfato plaquetario: efectos beneficiosos y limitaciones de las estrategias terapéuticas actuales y perspectivas futuras.
Rev Esp Cardiol, (2010), 63 pp. 60-76
[16.]
S.D. Wiviott, E. Braunwald, C.H. McCabe, G. Montalescot, W. Ruzyllo, S. Gottlieb, TRITON-TIMI 38 Investigators, et al.
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
N Engl J Med, (2007), 357 pp. 2001-2015
[17.]
L. Wallentin, R.C. Becker, A. Budaj, C.P. Cannon, H. Emanuelsson, C. Held, for the PLATO Investigators, et al.
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes.
N Engl J Med, (2009), 361 pp. 1-13
[18.]
C. Patrono, L.A. García Rodríguez, R. Landolfi, C. Baigent.
Low-dose aspirin for the prevention of atherothrombosis.
N Engl J Med, (2005), 353 pp. 2373-2383
[19.]
C. Gachet.
ADP receptors of platelets and their inhibition.
Thromb Haemost, (2001), 86 pp. 222-232
[20.]
F.J. Neumann, W. Hochholzer, G. Pogatsa-Murray, A. Schömig, M. Gawaz.
Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting.
J Am Coll Cardiol, (2001), 37 pp. 1323-1328
[21.]
D.P. Chew, D.L. Bhatt, S. Sapp, E.J. Topol.
Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials.
Circulation, (2001), 103 pp. 201-206
[22.]
J.E. Tcheng, S.G. Ellis, B.S. George, D.J. Kereiakes, N.S. Kleiman, J.D. Talley, et al.
Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.
Circulation, (1994), 90 pp. 1757-1764
[23.]
K. Peerlinck, I. De Lepeleire, M. Goldberg, D. Farrell, J. Barrett, E. Hand, et al.
MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man.
Circulation, (1993), 88 pp. 1512-1517
[24.]
R.A. Harrington, N.S. Kleiman, K. Kottke-Marchant, A.M. Lincoff, J.E. Tcheng, K.N. Sigmon, et al.
Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention.
Am J Cardiol, (1995), 76 pp. 1222-1227
[25.]
M.E. Bertrand, H.J. Rupprecht, P. Urban, A.H. Gershlick, CLASSICS Investigators.
Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS).
Circulation, (2000), 102 pp. 624-629
[26.]
M. Kazui, Y. Nishiya, T. Ishizuka, K. Hagihara, N.A. Farid, O. Okazaki, et al.
Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.
Drug Metab Dispos, (2010), 38 pp. 92-99
[27.]
N. Von Beckerath, D. Taubert, G. Pogatsa-Murray, E. Schömig, A. Kastrati, A. Schömig.
Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial.
Circulation, (2005), 112 pp. 2946-2950
[28.]
D. Soffer, I. Moussa, K.J. Harjai, J.A. Boura, S.R. Dixon, C.L. Grines, et al.
Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina?.
Catheter Cardiovasc Interv, (2003), 59 pp. 21-25
[29.]
D. Sibbing, O. Von Beckerath, A. Schömig, A. Kastrati, N. Von Beckerath.
Platelet function in clopidogrel-treated patients with acute coronary syndrome.
Blood Coagul Fibrinolysis, (2007), 18 pp. 335-339
[30.]
D.J. Angiolillo, D.L. Bhatt, P.A. Gurbel, L.K. Jennings.
Advances in antiplatelet therapy: agents in clinical development.
Am J Cardiol, (2009), 103 pp. A40-A51
[31.]
D.J. Angiolillo, P. Capranzano.
Pharmacology of emerging novel platelet inhibitors.
Am Heart J, (2008), 156 pp. S10-S15
[32.]
S.D. Wiviott, D. Trenk, A.L. Frelinger, M. O’Donoghue, F.J. Neumann, A.D. Michelson, PRINCIPLE-TIMI 44 Investigators, et al.
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
Circulation, (2007), 116 pp. 2923-2932
[33.]
G. Montalescot, S.D. Wiviott, E. Braunwald, S.A. Murphy, C.M. Gibson, C.H. McCabe, TRITON-TIMI 38 investigators, et al.
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Lancet, (2009), 373 pp. 723-731
[34.]
S.D. Wiviott, E. Braunwald, D.J. Angiolillo, S. Meisel, A.J. Dalby, F.W. Verheugt, TRITON-TIMI 38 Investigators, et al.
Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38.
Circulation, (2008), 118 pp. 1626-1636
[35.]
P.A. Gurbel, K.P. Bliden, K. Butler, U.S. Tantry, T. Gesheff, C. Wei, et al.
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Circulation, (2009), 120 pp. 2577-2585
[36.]
Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators.
Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
N Engl J Med, (1998), 338 pp. 1488-1497
[37.]
The PURSUIT Trial Investigators.
Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.
N Engl J Med, (1998), 339 pp. 436-443
[38.]
R.P. Giugliano, J.A. White, C. Bode, P.W. Armstrong, G. Montalescot, B.S. Lewis, EARLY ACS Investigators, et al.
Early versus delayed, provisional eptifibatide in acute coronary syndromes.
N Engl J Med, (2009), 360 pp. 2176-2190
[39.]
J.M. Ten Berg, A.W. Van ‘t Hof, T. Dill, T. Heestermans, J.W. Van Werkum, A. Mosterd, On-TIME 2 Study Group, et al.
Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome.
J Am Coll Cardiol, (2010), 55 pp. 2446-2455
[40.]
G.W. Stone, M.E. Bertrand, J.W. Moses, E.M. Ohman, A.M. Lincoff, J.H. Ware, ACUITY Investigators, et al.
Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.
JAMA, (2007), 297 pp. 591-602
[41.]
K. Huber, D.R. Holmes, A.W. Van ‘t Hof, G. Montalescot, P.E. Aylward, G.A. Betriu, et al.
Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial.
Eur Heart J, (2010), 31 pp. 1708-1716
[42.]
P.A. Gurbel, K.P. Bliden, K.A. Zaman, J.A. Yoho, K.M. Hayes, U.S. Tantry.
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
Circulation, (2005), 111 pp. 1153-1159
[43.]
T. Cuisset, C. Frere, J. Quilici, P.E. Morange, J.P. Mouret, L. Bali, et al.
Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders.
JACC Cardiovasc Interv, (2008), 1 pp. 649-653
[44.]
M. Valgimigli, G. Campo, N. De Cesare, E. Meliga, P. Vranckx, A. Furgieri, Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators, et al.
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study.
Circulation, (2009), 119 pp. 3215-3222
[45.]
S.V. Rao, J.A. Eikelboom, C.B. Granger, R.A. Harrington, R.M. Califf, J.P. Bassand.
Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes.
Eur Heart J, (2007), 28 pp. 1193-1204
[46.]
J.W. Eikelboom, S.R. Mehta, S.S. Anand, C. Xie, K.A. Fox, S. Yusuf.
Adverse impact of bleeding on prognosis in patients with acute coronary syndromes.
Circulation, (2006), 114 pp. 774-782
[47.]
G.W. Stone, B.T. McLaurin, D.A. Cox, M.E. Bertrand, A.M. Lincoff, J.W. Moses, ACUITY Investigators, et al.
Bivalirudin for patients with acute coronary syndromes.
N Engl J Med, (2006), 355 pp. 2203-2216
[48.]
G.W. Stone, B. Witzenbichler, G. Guagliumi, J.Z. Peruga, B.R. Brodie, D. Dudek, et al.
Bivalirudin during primary PCI in acute myocardial infarction.
N Engl J Med, (2008), 358 pp. 2218-2230
[49.]
M. De Carlo, G. Borelli, R. Gistri, N. Ciabatti, A. Mazzoni, M. Arena, et al.
Effectiveness of the transradial approach to reduce bleedings in patients undergoing urgent coronary angioplasty with GPIIb/IIIa inhibitors for acute coronary syndromes.
Catheter Cardiovasc Interv, (2009), 74 pp. 408-415
[50.]
A.J. Deibele, L.K. Jennings, J.E. Tcheng, C. Neva, A.D. Earhart, C.M. Gibson.
Intracoronary Eptifibatide Bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the intracoronary Eptifibatide (ICE) trial.
Circulation, (2010), 121 pp. 784-791
[51.]
J. Wöhrle, O.C. Grebe, T. Nusser, E. Al-Khayer, S. Schaible, M. Kochs, et al.
Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty.
Circulation, (2003), 107 pp. 1840-1843
[52.]
H. Thiele, K. Schindler, J. Friedenberger, I. Eitel, G. Fürnau, E. Grebe, et al.
Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.
Circulation, (2008), 118 pp. 49-57
[53.]
T.G. Wu, Q. Zhao, W.G. Huang, J.R. Wei, S.W. Chen, J. Zhao, et al.
Effect of intracoronary tirofiban in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
Circ J, (2008), 72 pp. 1605-1609
[54.]
A.Y. Fung, J. Saw, A. Starovoytov, C. Densem, P. Jokhi, S.J. Walsh, et al.
Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial.
J Am Coll Cardiol, (2009), 53 pp. 837-845
[55.]
M. O’Donoghue, E.M. Antman, E. Braunwald, S.A. Murphy, P.G. Steg, A. Finkelstein, et al.
The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
J Am Coll Cardiol, (2009), 54 pp. 678-685
Copyright ©
2011. Sociedad Española de Cardiología